The heparan sulfate mimetic Muparfostat aggravates steatohepatitis in obese mice due to its binding affinity to lipoprotein lipase.

Jia ZhangKai LiHao-Ran SunShao-Kun SunYa-Ting ZhuYu-Ting GeYu-Xuan WuQin-Yao ZhouGuan-Ting LiXiao-Ai ChangPeng Sun Ying Ding Xiao Han

Published in: British journal of pharmacology (2023)

The binding activity of HS mimetics to lipoprotein lipase should be investigated as an additional pharmacological effect during heparanase inhibitor drug discovery. This study also provides novel evidence for an increased risk of drug-induced liver injury in obese individuals.

Keyphrases

drug discovery
adipose tissue
metabolic syndrome
type diabetes
dna binding
binding protein
emergency department
atomic force microscopy
adverse drug
drug induced